Search

Your search keyword '"OVERALL survival"' showing total 1 results
1 results on '"OVERALL survival"'

1. ER+/HER2- breast cancer: Is first or second line CDK4/6 inhibitor therapy better?

Author

Kling, Jim

Subjects
*CYCLIN-dependent kinases, *BREAST cancer patients, *HER2 protein, *OVERALL survival, *CANCER survivors
Abstract

The article focuses on a study conducted by researcher Gabe Sonke and colleagues which found that advanced estrogen receptor-positive, human epidermal growth factor (HER)-negative breast cancer patients who received CDK4/6 inhibitors as first-line therapy did not outlive those who received the same as second-line therapy in terms of progression-free survival (PFS) or overall survival (OS). It states that in both the first and second-line applications, CDK4/6 have demonstrated efficacy.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results